Rhythm Pharmaceuticals, Inc. RYTM Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s long-term debt?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported long-term debt of $98.34M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s long-term debt changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s long-term debt decreased by 8.9% year-over-year, from $107.93M to $98.34M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s long-term debt?
- Over 2 years (2023 to 2025), Rhythm Pharmaceuticals, Inc.'s long-term debt has grown at a -2.5% compound annual growth rate (CAGR), from $106.14M to $100.89M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.